Industry rush on GLP‑1 weight‑loss drugs may threaten insulin focus, experts warn
Experts say pharma attention on GLP‑1 obesity medicines risks drawing resources away from diabetes supplies, potentially affecting access to insulin in low‑income countries, according to Guardian reports.

Pharmaceutical companies’ intense focus on GLP‑1 weight‑loss medicines could reduce attention on established diabetes therapies and threaten access to insulin, experts have warned.
According to reports in Guardian Science and Guardian Business, the Access to Medicine Foundation — in a recent analysis — cautioned that the industry’s “gold rush” around blockbuster GLP‑1 drugs is shifting priorities. The Foundation’s head told the Guardian outlets that while GLP‑1 medicines have transformed treatment for obesity and for some people with diabetes, the surge of interest in weight‑loss applications may divert company resources away from supplying and developing more basic diabetes care.
GLP‑1 products such as Ozempic, made by Novo Nordisk, and Mounjaro, from Eli Lilly, have become widely discussed for their effects on weight and metabolic disease, the Guardian reports say. At the same time, the publications note many people in lower‑income countries still struggle to obtain routine diabetes treatments, including insulin.
Why it matters
If manufacturers prioritize high‑margin GLP‑1 weight‑loss markets, the Guardian pieces say, there is a risk that investment, production capacity and corporate attention could shift away from the long‑standing needs of diabetes patients worldwide. The Access to Medicine Foundation’s findings and comments were reported by both Guardian outlets.
Sources
This story was written from reports by these outlets. Read the originals:



